NYSE:LLY - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	62,180	21,400	17,953	19,555	24
12/31/2025	52,622	16,553	13,140	15,599	27
12/31/2024	42,982	11,932	7,991	11,895	23
3/31/2024	35,932	6,138	-2,292	3,676	N/A
12/31/2023	34,124	5,240	-1,548	4,240	N/A
9/30/2023	32,073	4,988	1,374	5,713	N/A
6/30/2023	29,516	6,498	3,211	5,741	N/A
3/31/2023	27,691	5,687	3,881	6,793	N/A
12/31/2022	28,541	6,245	4,696	7,586	N/A
9/30/2022	29,240	6,033	5,404	8,080	N/A
6/30/2022	29,071	5,692	4,950	7,494	N/A
3/31/2022	29,323	6,129	5,824	8,086	N/A
12/31/2021	28,318	5,582	5,604	7,366	N/A
9/30/2021	27,759	5,972	4,621	6,919	N/A
6/30/2021	26,726	6,071	4,837	7,095	N/A
3/31/2021	25,486	6,093	5,565	7,815	N/A
12/31/2020	24,540	6,194	4,471	6,500	N/A
9/30/2020	23,214	5,573	5,112	6,648	N/A
6/30/2020	22,950	5,618	4,890	6,352	N/A
3/31/2020	23,087	5,533	3,684	4,908	N/A
12/31/2019	22,320	4,638	3,483	4,837	N/A
9/30/2019	21,843	4,264	2,671	4,322	N/A
6/30/2019	21,673	4,103	3,324	4,933	N/A
3/31/2019	21,622	2,545	2,217	5,399	N/A
12/31/2018	21,493	3,151	2,506	5,525	N/A
9/30/2018	22,016	372	2,100	5,819	N/A
6/30/2018	22,368	-166	1,711	5,579	N/A
3/31/2018	22,607	1,074	3,481	5,712	N/A
12/31/2017	19,974	-86	N/A	5,616	N/A
9/30/2017	22,471	2,225	N/A	5,879	N/A
6/30/2017	22,005	2,447	N/A	5,659	N/A
3/31/2017	21,585	2,187	N/A	5,410	N/A
12/31/2016	21,222	2,738	N/A	4,851	N/A
9/30/2016	20,837	2,444	N/A	3,841	N/A
6/30/2016	20,605	2,466	N/A	3,284	N/A
3/31/2016	20,179	2,319	N/A	2,830	N/A
12/31/2015	19,959	2,408	N/A	2,965	N/A
9/30/2015	19,704	2,359	N/A	3,318	N/A
6/30/2015	19,620	2,059	N/A	3,905	N/A
3/31/2015	19,577	2,192	N/A	4,010	N/A
12/31/2014	19,616	2,391	N/A	4,458	N/A
9/30/2014	20,303	2,690	N/A	4,744	N/A
6/30/2014	21,200	3,392	N/A	5,045	N/A
3/31/2014	22,194	3,865	N/A	5,628	N/A
12/31/2013	23,113	4,685	N/A	5,735	N/A
9/30/2013	23,262	4,785	N/A	5,610	N/A
6/30/2013	22,932	4,908	N/A	5,163	N/A

アナリストによる今後の成長予測

収入対貯蓄率: LLYの予測収益成長率 (年間27.3% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: LLYの収益 ( 27.3% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: LLYの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: LLYの収益 ( 16.3% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: LLYの収益 ( 16.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LLYの自己資本利益率は、3年後には非常に高くなると予測されています ( 62.4 %)。

Eli Lilly 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus EPS estimates increase by 11%

Eli Lilly and Company Raises Earnings Guidance for the Year 2024

Eli Lilly and Company Raises Earnings Guidance for the Year 2024

Price target increased by 11% to US$705

Eli Lilly and Company Provides Earnings Guidance for the Fiscal Year 2024

Recent updates

Eli Lilly and Company Declares Dividend for the Third Quarter of 2024, Payable on September 10, 2024

Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis)

Eli Lilly and Company Announces Detailed Results from the Surmount-OSA Phase 3 Clinical Trials Evaluating Tirzepatide Injection

Eli Lilly And Alzheimer's Disease: The Paucity Of Progress

Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval

These 4 Measures Indicate That Eli Lilly (NYSE:LLY) Is Using Debt Reasonably Well

Eli Lilly and Company Announces Resignation of Anat Ashkenazi as Chief Financial Officer, Effective July 2024

Insider notifies of intention to sell stock

Eli Lilly and Company Appoints Melissa Seymour as Executive Vice President of Global Quality and Member of the Executive Committee, Effective July 22, 2024

Eli Lilly and Company Announces Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

Eli Lilly's Growth And Challenges: A Cautious Buy

Eli Lilly: Addressing Supply Challenges Should Accelerate Growth

Eli Lilly and Company Announces Positive Topline Results from the Qwint-2 and Qwint-4 Phase 3 Clinical Trials Evaluating Once-Week Dosing

Eli Lilly and Company Announces Retirement of Alonzo Weems, Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer, Effective December 31, 2024

First quarter dividend of US$1.30 announced

Eli Lilly and Company Declares Dividend for the Second Quarter of 2024, Payable on June 10, 2024

Consensus EPS estimates increase by 11%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Eli Lilly: Bloated Stock

Eli Lilly and Company Raises Earnings Guidance for the Year 2024

Eli Lilly and Company Raises Earnings Guidance for the Year 2024

What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S

Eli Lilly and Company to Report Q1, 2024 Results on Apr 30, 2024

Wall Street Lunch: Lilly In Limelight

As You Sow Files an Exempt Solicitation Statement and Request Vote for the Proposal

Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets

SEIU Benefit Plans Master Trust Files a Notice of Exempt Solicitation to Eli Lilly and Company

Eli Lilly: The Party Is Not Over

Estimating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company Announces Results from A First-Of-Its-Kind Study of Lebrikizumab

Eli Lilly and Company to Present Donanemab in Early Symptomatic Alzheimer's Disease

New major risk - Financial position

Eli Lilly: Yes, It Is Too Late To Join The Party

Eli Lilly: Overvaluation Is A Big Red Flag

Philip Johnson to Retire as Eli Lilly and Company's Treasurer

Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade)

Price target increased by 11% to US$705

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of US$1.30 per share at 0.7% yield

Eli Lilly and Company Provides Earnings Guidance for the Fiscal Year 2024

Chairman exercised options and sold US$8.5m worth of stock

Insufficient new directors

Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value

Johna Norton to Retire as Lilly Executive Vice President of Global Quality

Eli Lilly and Company to Report Q4, 2023 Results on Feb 06, 2024

Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.30

Eli Lilly: The Cupboard Is Fully Stocked

Eli Lilly: The Buzz Is Not Over

Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.30

Eli Lilly and Company Launches End-To-End Digital Healthcare Experience Through LillyDirect

Eli Lilly and Company (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.

Eli Lilly (NYSE:LLY) Is Paying Out A Larger Dividend Than Last Year

Pinning Down Eli Lilly and Company's (NYSE:LLY) P/S Is Difficult Right Now

Eli Lilly: Long Path To A Trillion

Eli Lilly and Company Announces Updated Clinical Data from the International Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Eli Lilly and Company Declares Dividend for the First Quarter of 2024, Payable on March 8, 2024

Insider exercised options and sold US$1.3m worth of stock

Eli Lilly and Company Announces Availability of Zepbound (Tirzepatide) Injection

Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Jaypirca (Pirtobrutinib) for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphocytic Lymphoma

Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘